Literature DB >> 10693711

Lower extremity arteriography with use of iodinated contrast material or gadodiamide to supplement CO2 angiography in patients with renal insufficiency.

D J Spinosa1, J F Angle, K D Hagspiel, J A Kern, G D Hartwell, A H Matsumoto.   

Abstract

PURPOSE: To determine if the use of nonionic contrast material, as compared to the use of gadodiamide to supplement carbon dioxide angiography in patients with peripheral vascular disease (PVD) and chronic renal insufficiency (CRI), results in significant worsening of renal function.
MATERIALS AND METHODS: Lower extremity angiographic procedures (diagnostic and diagnostic/intervention) were performed in 40 patients with CRI (baseline serum creatinine [Cr] > 1.5 mg/dL) using CO2 alone or CO2 supplemented with the use of either nonionic contrast material or gadodiamide (up to 0.4 mmol/kg). Serum creatinine levels were obtained before the procedure and at 48 hours after the procedure. The peak Cr level was also determined for patients with a significant (> 0.5 mg/dL) Cr elevation.
RESULTS: Forty-two lower extremity angiographic procedures (19 diagnostic and 23 diagnostic/interventions) were performed in 40 consecutive patients from August 1997 to October 1998, with a mean preprocedure Cr of 2.2 mg/dL and a mean postprocedure Cr of 2.4 mg/dL. Twenty-five of the 40 patients (63%) had diabetes mellitus. Fifteen procedures, including six interventions, were performed utilizing CO2 and nonionic contrast material in 15 patients. Six of these 15 patients (40%) demonstrated a Cr increase > 0.5 mg/dL at 48 hours. Seven procedures, including two interventions, were performed with CO2 alone in seven patients. No patients in this group demonstrated an increase in serum creatinine of greater than 0.5 mg/dL at 48 hours. Twenty procedures, including 15 interventions, were performed with CO2 and gadodiamide in 18 patients. In one of these 20 procedures (5%) there was an increase in Cr > 0.5 mg/dL at 48 hours The difference in worsening renal function for the nonionic contrast group (six of 15) compared with the CO2/gadodiamide group (one of 20) was statistically significant (P = .03). When comparing the use of CO2 and nonionic contrast material versus CO2 alone and with gadodiamide (six of 15 versus one of 27), the difference is also statistically significant (P < .01). The average volume of supplemental contrast material was similar in the nonionic contrast material and gadodiamide groups, as was the average volume of supplemental nonionic contrast material in the six patients with an increased Cr.
CONCLUSION: The use of small volumes of nonionic contrast material to supplement CO2 angiography in patients with PVD and CRI can be associated with a significant increased risk of worsening renal function when compared to angiography performed with CO2 alone or CO2 and gadodiamide.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10693711     DOI: 10.1016/s1051-0443(07)61275-5

Source DB:  PubMed          Journal:  J Vasc Interv Radiol        ISSN: 1051-0443            Impact factor:   3.464


  8 in total

1.  Nephrotoxicity of gadolinium-based contrast in the setting of renal artery intervention: retrospective analysis with 10-year follow-up.

Authors:  Edwin A Takahashi; David F Kallmes; Kristin C Mara; William S Harmsen; Sanjay Misra
Journal:  Diagn Interv Radiol       Date:  2018-11       Impact factor: 2.630

2.  Contrast-induced nephropathy: what we know, what we think we know, and what we don't know.

Authors:  Brian Funaki
Journal:  Semin Intervent Radiol       Date:  2005-06       Impact factor: 1.513

3.  Gadolinium-based contrast agents: Stimulators of myeloid-induced renal fibrosis and major metabolic disruptors.

Authors:  Catherine Do; Bridget Ford; Doug Yoon Lee; Chunyan Tan; Patricia Escobar; Brent Wagner
Journal:  Toxicol Appl Pharmacol       Date:  2019-05-10       Impact factor: 4.219

4.  Iodine contrast iso-attenuating with diagnostic gadolinium doses in CTA and angiography results in ultra-low iodine doses. A way to avoid both CIN and NSF in azotemic patients?

Authors:  Ulf Nyman; Barbara Elmståhl; Håkan Geijer; Peter Leander; Torsten Almén; Mats Nilsson
Journal:  Eur Radiol       Date:  2010-08-29       Impact factor: 5.315

5.  Retrospective analysis of patients for development of nephrogenic systemic fibrosis following conventional angiography using gadolinium-based contrast agents.

Authors:  Hanno Hoppe; Sara Spagnuolo; Johannes M Froehlich; Helga Nievergelt; Hans-Peter Dinkel; Silvia Gretener; Harriet C Thoeny
Journal:  Eur Radiol       Date:  2009-09-16       Impact factor: 5.315

Review 6.  Actual clinical use of gadolinium-chelates for non-MRI applications.

Authors:  Holger M Strunk; H Schild
Journal:  Eur Radiol       Date:  2004-02-10       Impact factor: 5.315

7.  Contrast-induced nephropathy in patients undergoing percutaneous coronary intervention.

Authors:  Sana Shoukat; Saqib A Gowani; Asif Jafferani; Sajid H Dhakam
Journal:  Cardiol Res Pract       Date:  2010-09-19       Impact factor: 1.866

8.  Absence of potential gadolinium toxicity symptoms following 22,897 gadoteric acid (Dotarem®) examinations, including 3,209 performed on renally insufficient individuals.

Authors:  Laura K Young; Shona Z Matthew; J Graeme Houston
Journal:  Eur Radiol       Date:  2018-10-01       Impact factor: 5.315

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.